B cell depletion in autoimmune rheumatic diseases

被引：21
作者：
Pitashny, M
Shoenfeld, Y
机构：
[1] Chaim Sheba Med Ctr, Dept Internal Med B, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[4] Tel Aviv Univ, Incumbent Laura Schwarz Kipp Chair Res Autoimmune, IL-69978 Tel Aviv, Israel
来源：
AUTOIMMUNITY REVIEWS | 2005年 / 4卷 / 07期
关键词：
anti-CD20; rituximab; autoimmune diseases; B cell depletion;
D O I：
10.1016/j.autrev.2005.03.002
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Rituximab is a chimeric mouse-human monoclonal antibody, which binds to CD20, a B cell surface marker, leading to cell death by complement induced lysis and apoptosis. Since the introduction of this drug in the treatment of non-Hodgkin lymphoma, its applications have been extended to autoimmune diseases. This review summarizes the actual possible uses of this novel immune system targeted drug, and explains the mechanism of B cell depletion in autoimmune diseases. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码：436 / 441
页数：6
相关论文
共 22 条
  • [1] Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy
    Ahn, ER
    Lander, G
    Bidot, CJ
    Jy, W
    Ahn, YS
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2005, 78 (02) : 127 - 129
  • [2] DAMING S, BLOOD, V91, P1644
  • [3] Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
    Edwards, JCW
    Szczepanski, L
    Szechinski, J
    Filipowicz-Sosnowska, A
    Emery, P
    Close, DR
    Stevens, RM
    Shaw, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) : 2572 - 2581
  • [4] ERDOZAIN JG, 2004, HAEMATOLOGICA, V89, P34
  • [5] Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis
    Keogh, KA
    Wylam, ME
    Stone, JH
    Specks, U
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (01): : 262 - 268
  • [6] Kotzin BL, 2005, J RHEUMATOL, V32, P14
  • [7] Rituximab in the treatment of dermatomyositism - An opel-label pilot study
    Levine, TD
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (02): : 601 - 607
  • [8] Looney RJ, 2005, J RHEUMATOL, V32, P25
  • [9] B cell depletion as a novel treatment for systemic lupus erythematosus - A phase I/II dose-escalation trial of rituximab
    Looney, RJ
    Anolik, JH
    Campbell, D
    Felgar, RE
    Young, F
    Arend, LJ
    Sloand, JA
    Rosenblatt, J
    Sanz, I
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (08): : 2580 - 2589
  • [10] Maloney DG, 1997, BLOOD, V90, P2188
123